Introduction
Fli-1 is a member of the Ets gene family of transcription factors. Similar to other Ets proteins, Fli-1 functions as both a transcriptional activator and repressor with a highly conserved DNA-binding sequence called the Ets domain, recognizing a consensus GGA(A/T) core motif. Additionally, deregulated expression of Ets proteins is associated with aberrant development and malignant transformation. 1 Fli-1 is preferentially expressed in vascular endothelial cells and hematopoietic tissues, including the thymus and spleen, and has been shown to play an important role in their development. 2, 3 Given the expression profile of Fli-1, its aberrant regulation would be expected to result in vascular and/or hematopoietic abnormalities, and indeed, the discovery of fli-1 is attributed to its role in the initiation and progression of erythroleukemogenesis in mice.
Earlier studies of genes associated with retroviral-induced neoplasias have contributed to our understanding of gene function, as well as to the processes of differentiation and transformation. A prime example of this is erythroleukemia induced by Friend Murine Leukemia Virus (F-MuLV). Upon injection of F-MuLV, strain-specific neonates develop a multistage disease characterized by erythroblastic expansion leading to anemia, splenomegaly, and eventually death within 8 weeks of injection. Viral integration at the fli-1 locus drives Fli-1 overexpression, and has been identified as the pivotal genetic event associated with this disease. 2 Fli-1 viral integration is followed by further changes in the expression of anti-apoptotic and tumor suppressor genes, as well as the modification of erythropoietin (Epo), resulting in Epo-independent proliferation of erythroblasts and fully leukemic clones. 4 Moreover, Fli-1 has been reported to regulate an array of genetic targets, such as Rb, MDM2 and bcl-2, whose roles in malignancy have been well established. [5] [6] [7] The study of F-MuLV-induced erythroleukemia has also provided insight into the non-pathological role of Fli-1. Constitutive activation of fli-1 in erythroblasts alters their responsiveness to Epo, switching the signaling events associated with terminal differentiation to proliferation. 5, 8, 9 While aberrant Fli-1 expression is associated with viral integration in mice, it is also associated with several human disorders. In Ewing's sarcoma and primitive neuroectodermal tumors, a translocation between chromosome 11 and 22, t(11;22) (q24;q12) results in a chimeric EWS/Fli-1 fusion protein detectable in 85% of these tumors. This fusion protein contains the carboxy-terminal Ets domain of Fli-1 with the aminoterminal RNA binding domain of EWS. 10 The EWS/Fli-1 fusion protein functions as a transcriptional activator causing the initiation and progression of this disease, and possesses a strong transforming ability in fibroblasts mediated through the Ets domain. 11 Additionally, a group examining the expression of Fli-1 in several benign and malignant neoplasms has further implicated the importance of fli-1 aberrant regulation in tumor progression. 12 These observations emphasize a role for aberrant fli-1 regulation in the initiation of malignancies such as erythroleukemia and Ewing's sarcoma. However, the molecular mechanisms underlying such transformations remain unclear. Modulating Fli-1 expression, such as by RNA interference (RNAi) and dominant-negative studies, should provide a better understanding of fli-1 function and help to further elucidate its role in pathological occurrences.
We hypothesized that modulating Fli-1 expression, would impact the survival, proliferation and differentiation of erythroleukemia cells. Here we provide evidence to suggest that continuous Fli-1 expression is necessary for the maintenance and survival of several malignant phenotypes.
Materials and methods

Cell lines
The murine erythroleukemia cell lines, CB3 and HB22.2, were maintained in a-minimum essential medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco). The human erythroleukemia cell line, HEL, and the human myelogenous leukemia cell line, K562, were maintained in RPMI-1640 medium (Gibco) supplemented with 10% FBS (Gibco). The murine erythroleukemia cell line, HB60-5, was maintained in the same medium supplemented with 0.2 U of Epo and 100 Zg of stem cell factor per ml. To induce differentiation, HB60-5 cells were washed twice with phosphate-buffered saline (PBS) (Gibco) and incubated in the presence of 10% FBS and 1 U of Epo per ml. The mouse fibroblast cell line, NIH-3T3, and the human embryonic kidney cell line, 293T, were cultured in Dulbecco's Modified Eagle's Medium (Gibco) supplemented with 10% FBS (Gibco).
RNA interference
Pre-designed fli-1 small interfering RNA sequences were purchased from Ambion (Ambion/Applied Biosystems, Foster City, CA, USA) to design small hairpin RNA (shRNA) oligonucleotides containing a hairpin loop sequence (5 0 -TTCAAGAGA-3 0 ) and an RNA Polymerase III terminator sequence consisting of a six-nucleotide poly(T) tract. Additionally, a 5 0 -BamH1 restriction site was inserted in the top strand and a 5 0 -EcoR1 restriction site was inserted in the bottom strand of the shRNA oligonucleotides to enable directional cloning into the pSIREN RetroQ ZsGreen retroviral vector (Clontech, Takara Bio Inc., Mountain View, CA, USA). A unique XbaI restriction site was also inserted immediately downstream of the terminator sequence to confirm the presence of shRNA oligonucleotide inserts. Complementary polyacrylamide gel electrophoresis-purified shRNA oligonucleotides, synthesized by Sigma Aldrich/Sigma Genosys Canada (Oakville, ON, Canada), were annealed in a thermal cycler (95 1C for 30 s, 72 1C for 2 min, 37 1C for 2 min, 25 1C for 2 min). Additionally, a negative control shRNA-annealed oligonucleotide, provided by Clontech, was cloned into the same retroviral vector. The negative control shRNA contains the same nucleotide composition as the fli-1 shRNA oligonucleotide, but lacks sequence homology to the genome. The annealed double stranded oligonucleotides were ligated into the pSIREN vector (Clontech), using T4 DNA ligase (New England Biolabs, Pickering, ON, Canada).
RNAi virus production
The RNAi-ready retroviral vectors were triple-transfected with Lipofectamine 2000 (Invitrogen, Burlington, ON, Canada) into 293T cells, following the manufacturer's protocol (Invitrogen). The vesicular stomatitis virus G glycoprotein (VSVG)-expressing vector as well as the vector expressing the gag and pol viral packaging signals were kindly provided by Dr Dwayne Barber (University of Toronto, Canada). Viral supernatant was collected 48, 72 and 96 h post-transfection and concentrated by ultracentrifugation at 25 000 rpm for 2 h. The virus was resuspended in approximately 1/50 of the original volume. CB3 cells (2.5 Â 10 6 ) were infected with 2 ml of concentrated virus, in the presence of polybrene (10 mg/ml final concentration), as described earlier. 
Cell proliferation assay
The growth rate of each erythroleukemic cell line was examined in low-serum media, containing 1% FBS. NIH-3T3 cells (5 Â 10 3 cells) were seeded in triplicates in 3 cm wells with low-serum media and cell proliferation was measured by performing Trypan-blue exclusion assay.
Soft agar assays
In each experiment, 5 Â 10 3 cells of each cell line were trypsinized and resuspended in 2 ml of complete medium in 0.3% agarose (Promega, Madison, WI, USA). The agar-cell mixtures were plated in triplicate on plates containing a 1% complete medium agar mixture. After 2-3 weeks, the agar assays were scored for viable colonies.
RNA extraction and reverse transcription PCR
Total RNA was extracted using TRIZOL (Gibco), according to the manufacturer's protocol, and treated with amplification grade DNaseI (Invitrogen) to avoid amplification of contaminated genomic DNA. Complementary DNA was synthesized with SuperScript II Reverse Transcriptase (Invitrogen). PCR primers were as follows: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forward primer: 5 0 -AACTTTGGCATTGTG GAAGG-3 0 , reverse primer:
0 -CCTTTCCAGGGCTTCAGCTCCATAT-3 0 . Gel images were scanned using Quantity One software (Bio-Rad, Mississauga, Canada).
Flow cytometric cell cycle analysis
Single parameter analysis of DNA content was performed on cells fixed in 70% ethanol, washed twice with PBS (Gibco) and resuspended in staining solution containing 500 ml RNaseA (200 U/ml) (Sigma Aldrich, Oakville, ON, Canada) and 500 ml propidium iodide (50 g/ml) (Molecular Probes, Eugene, OR, USA). Linear fluorescence signals of propidium iodide (area and width) were assessed on a BD FACSCalibur (BD Biosciences, San Jose, CA, USA) with dye excitation by a 488 nm laser light. Data were stored as mode files of at least 5 Â 10 3 single cell events for subsequent off-line analysis using Modfit and WinList software (Verity Software, Topsham, ME, USA). DNA cell cycle analysis was accomplished using the DIP_N2 and DIP_N3 algorithms in Modfit.
Immunoblotting and antibodies
Cells were lysed with radioimmunoprecipitation assay buffer (0.5% Nonidet P-40, 50 mM Tris HCl (pH 8.0), 120 mM NaCl, 50 mM NaF, 10 g of aprotinin per ml, 100 g of leupeptin per ml, 10 mM phenylmethylsulfonyl fluoride). Lysates were resolved on sodium dodecyl sulfate-10% polyacrylamide gels, and immunoblotted as described elsewhere. 15 Antibodies to Fli-1 and b-actin were obtained from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Images were scanned using Quantity One software (Bio-Rad).
Immunohistochemistry
293T cells were plated at a density of 1 Â 10 6 cells per poly-Lleucine-coated glass coverslip (Assistent, Germany) in six-well plates. After 24 h, cells were transfected with the MigR1 empty control vector, MigR1-Fli-1, or MigR1-En/Fli-1, using Lipofectamine 2000 (Invitrogen) following the manufacturer's protocol. Immunocytochemical staining was performed 48 h posttransfection. Coverslips were fixed with cold (4 1C) 4% paraformaldehyde at room temperature for 10-20 min, permeabilized with absolute methanol at À20 1C for 7 min, washed thrice with PBS (Gibco) and blocked in 10% normal horse serum (PAA Laboratories GmbH, Germany). After blocking, cells were incubated with Fli-1 polyclonal antibody (Santa Cruz Biotechnology) overnight at 4 1C, washed thrice with PBS (Gibco), incubated with biotinylated goat anti-rabbit IgG antibody and avidin-biotinylated peroxidase solution (Santa Cruz Biotechnology), and washed again. Antibody binding was revealed using 3,3 0 -diaminobenzidine-glucose oxidase for 15 min. Counterstaining was performed with hematoxylin. For immunohistochemical controls, the primary antibody was omitted.
Luciferase reporter assay
293T cells (10 6 cells) were plated in six-well plates and transfected 24 h later with the indicated amount of plasmid DNA using Lipofectamine 2000 (Invitrogen), as recommended by the manufacturer. The DNA mixture used for transfection includes the indicated amounts of reporter gene constructs (pGL4.28 vector and pGL4.28-FB) and expression plasmids (MigR1 empty vector, MigR1-Fli-1, MSCV empty vector and MSCV-EWS/Fli-1). Cell lysates were prepared 48 h after transfection and assayed for luciferase activity by using the luciferase assay system kit (Promega). The results shown are the mean of at least three independent transfection experiments. To account for transfection efficiency, b-gal concentrations were used to normalize results. 13 
Results
Fli-1 downregulation in erythroleukemic cells by RNAi leads to a marked growth inhibition and cell death
Retroviral vectors were cloned to express functional fli-1 shRNAs or negative control shRNAs under the control of U6 RNA Polymerase III-dependent promoter. These shRNA retroviral expression plasmids were triple-transfected into 293T cells with plasmids expressing either the gag and pol packaging signals or the vesicular stomatitis virus glycoprotein envelope protein. Concentrated viral supernatants were used to infect the F-MuLV-induced erythroleukemia cell line, CB3, expressing high endogenous levels of Fli-1. Initial microscopic observation and cell counting with Trypan blue showed that fli-1 shRNAtreated cells exhibited significantly reduced proliferation rate ( Figure 1a ) and increased cell death compared with the appropriate controls (Figure 1b) .
To validate the efficacy of RNAi-mediated Fli-1 downregulation, as well as to correlate growth inhibition and cell death with this downregulation, we analyzed an unsorted population of CB3 cells 24 h postinfection. Indeed, western blot analysis confirmed the efficacy of Fli-1 knockdown (Figure 1c ). These data provide evidence to suggest that continuous Fli-1 overexpression is essential for the survival and proliferation of erythroleukemic cells. However, constitutive suppression of Fli-1 through RNAi is extremely toxic to erythroleukemia cells and the rapid onset of cell death has made further examination difficult. Therefore, additional analyses were necessary to investigate this phenomenon. Figure 1) .
En
To investigate the efficacy of En/Fli-1 to inhibit the transactivating ability of Fli-1, luciferase assays were performed using a vector with the Fli-1 Ets DNA-binding site cloned upstream of the luciferase gene, designated pGL4.28-FB. Figure 2b shows that exogenous expression of both Fli-1 and EWS/Fli-1 in 293T cells increased the luciferase activity of the pGL4.28-FB reporter gene in a dose-dependent fashion, as compared with the empty vector, pGL4.28. As expected, EWS/Fli-1 expression displayed more robust luciferase activity than Fli-1 (Figure 2b) . [20] [21] [22] Co-transfection of the En/Fli-1 expression vector with either Fli-1 or EWS/Fli-1 expression vectors decreased luciferase activity as compared with cells transfected with either Fli-1 or EWS/Fli-1 vectors alone (Figure 2b) . Additionally, the luciferase reporter carrying point mutations within the Fli-1 binding site exhibited the same level of luciferase activity as the empty luciferase vector (data not shown).
En/Fli-1 represses the transforming ability of EWS/Fli-1 in transformed NIH-3T3 cells
As EWS/Fli-1 has the same Ets binding site as Fli-1, En/Fli-1 was examined for its ability to repress or inhibit EWS/Fli-1-mediated NIH-3T3 cell transformation. To do so, we generated a stable NIH-3T3 cell line overexpressing mouse EWS/Fli-1, En/Fli-1 or Fli-1 (Figure 2c) . It is well known that one of the hallmarks of a transformed phenotype is the ability of cells to grow in semisolid medium. Soft agar assays showed that empty vector transfected NIH-3T3 cells grew poorly in this condition as only 15 ± 10 small colonies per 5000 cells plated were counted (Figure 2d En/Fli-1 reduces the proliferation rate of EWS/Fli-1-transformed NIH-3T3 cells in low-serum media Under normal culture conditions of 10% FBS supplemented medium, no significant difference could be detected in the growth rate of both wild type or EWS/Fli-1-transformed NIH-3T3 cells co-transfected with En/Fli-1 retrovirus (data not shown). However, under low-serum culture conditions (1% FBS), the EWS/Fli-1-transformed cells grew rapidly, whereas proliferation in the control cells remained unchanged (Figure 2e ). EWS/Fli-1-transformed cells co-transfected with En/Fli-1 displayed a significantly reduced proliferation rate, similar to the rate of control-transfected cells (Figure 2e) . Thus, En/Fli-1 expression was able to inhibit the proliferation of EWS/Fli-1-transformed cells in low-serum growth conditions.
En/Fli-1 suppresses proliferation of erythroleukemic cells overexpressing Fli-1
The aforementioned results suggested the ability of En/Fli-1 to inhibit the transactivating activity of Fli-1 and EWS/Fli-1 as well as to suppress the transforming ability of the latter. Therefore, to further establish the critical role of continuous Fli-1 overexpression in malignant transformation, En/Fli-1 was introduced into an F-MuLV-induced erythroleukemia cell line termed CB3, which overexpresses Fli-1 23 ( Figure 3a) . 3 days postinfection with either En/Fli-1 or control vector retroviruses, green fluorescent protein-positive cells were sorted by flow cytometry prior to immunoblotting and growth rate analysis (Figures 3b  and c) . Similar to our earlier RNAi experiments, the proliferation rate of CB3 cells was significantly attenuated after infection with the En/Fli-1 retroviral expression vector (Figure 3c ). Accordingly, cell cycle analysis using propidium iodide revealed that CB3 cells expressing En/Fli-1 display a decreased proportion of cells in S phase (Figure 3d ) and revealed an apoptotic population, as evidenced by the appearance of a sub-G1 peak (Figure 3d ). It is likely that Fli-1 overexpression contributes to the anti-apoptotic phenotype through direct regulation of its target genes.
The anti-apoptotic gene, bcl-2, overexpressed in F-MuLVinduced erythroleukemias, 24 has previously been shown to be a direct Fli-1 target gene, and Fli-1-mediated Bcl-2 upregulation contributes to the enhanced survival of erythroblasts. 6 Consequently, the direct transcriptional regulation of Fli-1 target genes, such as bcl-2, is thought to contribute to the transforming ability of Fli-1 in erythroleukemic cells. Therefore, as En inhibits the ability of Fli-1 to act as a transcriptional repressor or activator, we examined bcl-2 expression in En/Fli-1-expressing CB3 cells. Indeed, reverse transcription-PCR analysis revealed significantly reduced levels of bcl-2 in these cells as compared with the empty vector control infected cells (Figure 3e) .
The role of Fli-1 inactivation was further examined in other F-MuLV-induced erythroleukemia cell lines overexpressing Fli-1, termed HB60-5 and HB22.2 ( Figure 3a) . As expected, En/Fli-1 expression in both cells lines (Figure 3f ) also results in a marked growth inhibition (Figure 3g) . Interestingly, this phenomenon is rescued over time through the loss of En/Fli-1 expression (Figure 4 ). HB60-5 cells, infected with the control or En/Fli-1 retroviral expression vector, were sorted by flow cytometry at 3 and 12 days postinfection. En/Fli-1 protein expression and growth rates were examined in each population. The expression of the dominant negative fusion protein was lost 12 days postinfection and was associated with a proliferation profile identical to that of the control cells (Figure 4) . Together, these results confirm a similar phenomenon observed with RNAi-mediated Fli-1 downregulation, suggesting that continuous Fli-1 overexpression is required for the proliferation and survival of murine erythroleukemic cells.
En/Fli-1 inhibits proliferation of human erythroleukemic cells in culture
Similar to F-MuLV-induced erythroleukemia cell lines, the human erythroleukemia cell line, HEL, also displays aberrant fli-1 expression (Figure 3a) . The importance of continuous Fli-1 overexpression was examined in HEL cells by introduction of the En/Fli-1 retrovirus (Figure 5a ). Expression of En/Fli-1 in HEL cells (Figure 5a ), similar to murine erythroleukemic cells (Figure 3 ), resulted in a reduced proliferation rate (Figure 5b) . Moreover, similar to the murine erythroleukemic cells, the expression of En/Fli-1 was lost after 12 days of culture (data not shown). These data for the first time display the importance of Fli-1 expression in the maintenance of human erythroleukemia.
En/Fli-1 promotes differentiation of erythroid progenitors transformed by Fli-1
The F-MuLV-induced erythroleukemia cell line, HB60-5, proliferates in the presence of Epo and stem cell factor, but undergoes terminal differentiation in the presence of Epo alone. 5 We have revealed earlier that ectopic expression of Fli-1 in these cells blocks erythroid differentiation by switching Epoinduced differentiation to Epo-induced proliferation. 5 To further verify the role of Fli-1 in erythroid differentiation, we introduced En/Fli-1 in HB60-5 cells overexpressing Fli-1, designated HB60-5-Fli-1 (Figure 6a ). Additionally, our earlier studies have shown that the expression of a-globin, a differentiation marker for erythroid cells, is elevated in response to Epo in HB60-5 cells. However, Fli-1 overexpression in these cells inhibits this response. 5 When both HB60-5-Fli-1 and En/Fli-1-expressing HB60-5-Fli-1 cells were grown in the presence of Epo, an increased level of a-globin was detected in En/Fli-1-expressing cells (Figure 6b ), indicating that En/Fli-1 expression reversed the inhibitory effect on erythroid differentiation caused by Fli-1 overexpression.
Discussion
F-MuLV-induced erythroleukemia is a well-established tumor model that is aptly suited for studying the mechanisms governing the proliferation, maturation and transformation of erythroid progenitor cells. 25 The activation of fli-1 through retroviral insertion in erythroleukemia induced by F-MuLV is a critical initial step in the multistage development of this leukemia.
2 F-MuLV studies involving examination of the role of fli-1 in erythropoiesis have suggested that constitutive Fli-1 expression dramatically increases the self-renewal potential of pro-erythroblasts and blocks erythroid differentiation. 5 Conversely, transgenic mice generated to overexpress Fli-1 do not develop erythroleukemia, but instead exhibit increased lymphopoiesis, splenomegaly, accumulation of abnormal B and T cells and develop a severe lupus-like autoimmune disease, ultimately resulting in death. 26 Mice carrying a targeted deletion in the Ets domain at the fli-1 locus display abnormal hematopoiesis and vasculogenesis, and die between embryonic day 11.5 and 12.5. 27, 28 The first targeted disruption at the fli-1 locus, deleting the first ATG start site, resulted in the expression of a truncated protein and generated a non-lethal minor phenotype, including a reduction in thymus size and in the number of total thymocytes. 29 Interestingly, these mice remain susceptible to the development of erythroleukemia following infection with F-MuLV, however, the latency period is significantly increased. 29 Although these observations implicate that Fli-1 overexpression is vital for the initiation and progression of erythroleukemia, the molecular mechanisms underlying the role of aberrant fli-1 regulation in oncogenesis remains poorly understood.
To assess the role of Fli-1 overexpression in the maintenance and survival of murine erythroleukemia, we downregulated Fli-1 expression using RNAi. RNAi-mediated suppression of Fli-1 in F-MuLV-induced erythroleukemia cells results in reduced proliferation associated with rapid cell death. Owing to the toxicity of constitutive Fli-1 suppression and to further investigate this phenomenon, we generated a dominant negative form of Fli-1, termed En/Fli-1. In this system, ectopic expression of this dominant-negative fusion protein mimics a loss-of-function allele. This approach has also been successful in inhibiting the function of the Ets-related gene Erg (F Rizzo and MI Arnone unpublished data/personal communication), plant transcription factors, 17 as well as b-catenin, 18 and c-myb. 19 A luciferase assay confirmed the ability of En/Fli-1 to act as a transcriptional repressor, capable of inhibiting the transactivating activity of Fli-1, as well as that of the oncogenic fusion protein EWS/Fli-1. This oncoprotein, generated by a chromosomal translocation in Ewing's sarcoma and primitive neuroectodermal tumors, is a potent transcriptional activator containing the strong transactivating domain of EWS and the Ets DNA-binding domain of Fli-1, with a more powerful transforming ability than fli-1. [20] [21] [22] 30 We show that expression of the En/Fli-1 repressor impairs anchoragedependent growth of EWS/Fli-1-transformed NIH-3T3 cells and reduces the proliferation rate of these cells in low-serum media. Although En/Fli-1 does not completely inhibit the transforming ability of EWS/Fli-1, these experiments imply that the oncogenic potential of EWS/Fli-1 at least, in part, is attributed to the transactivating activity of the Fli-1 Ets DNA-binding domain. However, the strong transactivation domain from EWS may permit enhanced or novel interactions with genes not normally responsive to Fli-1 to disrupt normal growth and differentiation. 30, 31 These results support an earlier study showing that the expression of small interfering RNAs targeting the fusion between EWS and fli-1 slows the proliferation rate of a Ewing's sarcoma cell line, and the expression of fli-1 small interfering RNAs in these cells further potentiates this effect. 32 Moreover, a recent study has shown that mice expressing EWS/Fli-1 develop a rapid onset of myeloid/erythroid leukemia that closely resembles F-MuLV-induced erythroleukemia. 33 Furthermore, cell cycle analysis revealed the ability of En/Fli-1 to suppress growth and induce apoptosis in an F-MuLV-induced erythroleukemia cell line. Interestingly, Fli-1 suppression also attenuates the growth rate of the human erythroleukemia cell line, HEL. This study, for the first time, provides evidence to suggest that Fli-1 plays an essential role in the proliferation of human erythroleukemia.
Fli-1 downregulation, mediated through RNAi or expression of the dominant-negative En/Fli-1 fusion protein, confirmed the essential role of fli-1 in the regulation of cellular proliferation and survival. 34, 35 We have shown that En/Fli-1 expression is only tolerated for a short period after its introduction into erythroleukemia cells. Additionally, the loss of Fli-1 activity in these cells is associated with a marked growth inhibition and apoptosis. Previously, Fli-1 has been shown to activate transcription of the anti-apoptotic gene, bcl-2. 6 To this respect, the expression of bcl-2 in CB3 cells infected with En/Fli-1 was much lower than cells infected with the control vector alone. These data suggest that the fli-1 proto-oncogene contributes to cell survival, at least in part, by the upregulation of bcl-2 in erythroleukemic cells, 24 resulting in evasion of the normal apoptotic program.
In addition to inhibition of apoptosis, Fli-1 overexpression in erythroid cells is also shown to inhibit erythroid differentiation, leading to massive proliferation, in response to Epo. 5 Indeed, ectopic expression of Fli-1 in the HB60-5 erythroleukemia cell line switches Epo-induced differentiation to Epo-induced proliferation. To verify the role of Fli-1 in differentiation, we have shown that the expression of En/Fli-1 in HB60-5 cells overexpressing Fli-1 increases their differentiation status, as measured through the expression of a-globin.
In summary, the experiments described here suggest, for the first time, an essential role for continuous Fli-1 overexpression in the proliferation and survival of murine and human erythroleukemias. It appears that Fli-1 has the potential to alter these cellular processes, likely through the regulation of several target genes. The approach used in this study could eventually provide potential avenues for the elucidation of fli-1 function in malignant transformation through identification of additional genes regulated by this transcription factor. Furthermore, these findings reveal that Fli-1 downregulation may have important implications in the pathogenesis of diseases, such as erythroleukemia, and perhaps provide clues to novel treatment options.
